GH Research says Phase 2b trial shows GH001 cuts anhedonia scores in TRD

• GH Research presented a poster at the American Society of Clinical Psychopharmacology meeting in May 2026, reporting a post-hoc analysis from its Phase 2b trial of inhaled mebufotenin (GH001) in treatment-resistant depression.
• The analysis indicated patients treated with GH001 saw a rapid improvement in anhedonia symptoms versus placebo, with benefits described as sustained among patients who continued into a six-month open-label extension with infrequent re-treatment.
• The readout supports the drug’s positioning on a high-impact depression symptom cluster tied to day-to-day functioning, potentially strengthening the clinical narrative for future development and partnering or financing discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-022330), on May 21, 2026, and is solely responsible for the information contained therein.